Leerink Swann Initiates Coverage On Oruka Therapeutics with Outperform Rating, Announces Price Target of $44
Portfolio Pulse from Benzinga Newsdesk
Leerink Swann has initiated coverage on Oruka Therapeutics with an Outperform rating and set a price target of $44.

September 17, 2024 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Swann has initiated coverage on Oruka Therapeutics with an Outperform rating and a price target of $44, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $44 by a reputable analyst firm like Leerink Swann is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100